Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape

Zou, Xueqin; Zhao, Yangjing; Liang, Xiuting; Wang, Hui; Zhu, Yanling; Shao, Qixiang

doi:10.3389/fimmu.2021.641937

Cited by 4 publications

(3 citation statements)

References 132 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Robust data suggest an EMT association with platinum resistance in ovarian cancer. MicroRNAs mediate platinum resistance or sensitivity by regulating EMT [ 87 ]. MiR-186 downregulation was associated with EMT and chemoresistance by targeting Twist1 in ovarian cancer cell lines [ 88 ].…”

Section: Molecular Mechanisms Of Platinum Resistance In High-grade Ov...mentioning

confidence: 99%

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It

et al. 2023

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecologic malignancy. Platinum-based chemotherapy is the backbone of treatment for ovarian cancer, and although the majority of patients initially have a platinum-sensitive disease, through multiple recurrences, they will acquire resistance. Platinum-resistant recurrent ovarian cancer has a poor prognosis and few treatment options with limited efficacy. Resistance to platinum compounds is a complex process involving multiple mechanisms pertaining not only to the tumoral cell but also to the tumoral microenvironment. In this review, we discuss the molecular mechanism involved in ovarian cancer cells’ resistance to platinum-based chemotherapy, focusing on the alteration of drug influx and efflux pathways, DNA repair, the dysregulation of epigenetic modulation, and the involvement of the tumoral microenvironment in the acquisition of the platinum-resistant phenotype. Furthermore, we review promising alternative treatment approaches that may improve these patients’ poor prognosis, discussing current strategies, novel combinations, and therapeutic agents.

show abstract

Section: Molecular Mechanisms Of Platinum Resistance In High-grade Ov...mentioning

confidence: 99%

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It

et al. 2023

View full text Add to dashboard Cite

show abstract

“…During the recent decade, there are gradually increasing studies showing that microRNAs specifically target mRNAs to participate in the formation of platinum resistance and immune escape in ovarian cancer ( 14 – 16 ). For instance, the overexpression of miR-30b can induce platinum resistance by inhibiting the expression of MYPT1 ( 17 ), whereas miR-211 has been confirmed to improve the platinum sensitivity of ovarian cancer cells by inhibiting the expression of the multiple genes involved in the DNA damage response ( 18 ).…”

Section: Introductionmentioning

confidence: 99%

MiR-320b and miR-320d as Biomarkers to Predict and Participate in the Formation of Platinum Resistance in Ovarian Cancer Patients

et al. 2022

View full text Add to dashboard Cite

Patients with ovarian cancer who receive platinum-based chemotherapy typically develop platinum resistance, which leads to tumor recurrence and mortality. Therefore, finding the underlying mechanisms and biomarkers is critical. A total of 51 platinum-resistant and 70 platinum-sensitive ovarian cancer patients were enrolled in this study. We examined the GSE131978 dataset in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus database for differentially expressed long non-coding RNAs and messenger RNAs (mRNAs) between platinum-resistant and platinum-sensitive patients and completed a microRNA chip analysis. After filtering by Pearson correlation analysis, the competitive endogenous RNA (ceRNA) networks were subsequently constructed. Then, the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology enrichment analyses about mRNAs in ceRNA networks were accomplished. More crucially, we demonstrated the differentially expressed microRNAs using quantitative real-time PCR and fluorescence in situ hybridization. The feasibility of microRNAs as biomarkers to predict platinum resistance and tumor recurrence was assessed using the receiver operating characteristic curve and survival analysis. MiR-320b and miR-320d exhibited high area under the curve values of 0.757 and 0.702, respectively. In our study, ceRNA networks including miR-320b and miR-320d probably provided novel insights for platinum resistance in ovarian cancer patients.

show abstract

“…However, the therapeutic effect is short-lived and relapse often occurs [3,4]. In ovarian cancer, the low effectiveness of chemotherapy results not only from the drug resistance of cancer cells, but also from the suppression of the antitumor activity of the immune system in the tumor microenvironment [5][6][7]. Adenosine inhibits the biological functions of various immune cells in the tumor environment by interacting with adenosine receptors located on the cell surface, mainly on leukocytes.…”

Section: Introductionmentioning

confidence: 99%

Interaction of Adenosine, Modified Using Carborane Clusters, with Ovarian Cancer Cells: A New Anticancer Approach against Chemoresistance

Bednarska-Szczepaniak

Przelazły

Kania

et al. 2021

Cancers

View full text Add to dashboard Cite

Platinum compounds remain the first-line drugs for the treatment of most lethal gynecological malignancies and ovarian cancers. Acquired platinum resistance remains a major challenge in gynecological oncology. Considering the unique physicochemical properties of the metallacarboranes modifier and the significant role of nucleoside derivatives as anticancer antimetabolites, we designed and synthesized a set of adenosine conjugates with metallacarboranes containing iron, cobalt, or chromium as semi-abiotic compounds that influence the cisplatin sensitivity of ovarian cancer cells. Adherent cultures of ovarian carcinoma cell lines and multicellular spheroids, ranging from sensitive to highly resistant including experimental cell lines “not responding” to platinum drugs were used. Iron-containing metallacarborane conjugates showed the best anticancer activity, especially against resistant cells. Compound modified at the C2′ nucleoside position showed the best activity in resistant cancer cells and highly resistant cancer spheroids exposed to cisplatin, increasing cell cycle arrest, apoptosis or necrosis, and reactive oxygen species production. Moreover, it showed high cellular accumulation and did not induce cross-resistance to cisplatin, carboplatin, doxorubicin, paclitaxel, or gemcitabine in long-term cultures. The reference nido-carborane derivative (no metal ions) and unmodified nucleosides were not as effective. These findings indicate that metallacarborane modification of adenosine may sensitize ovarian cancer cells to cisplatin in combination treatment.

show abstract

Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape

Cited by 4 publications

References 132 publications

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It

MiR-320b and miR-320d as Biomarkers to Predict and Participate in the Formation of Platinum Resistance in Ovarian Cancer Patients

Interaction of Adenosine, Modified Using Carborane Clusters, with Ovarian Cancer Cells: A New Anticancer Approach against Chemoresistance

Contact Info

Product

Resources

About